Date: 2012-10-08
Type of information: Initiation of the trial
phase: 1
Announcement: authorization of a phase 1 study
Company: The Jenner Institute (UK) Isconova (Sweden)
Product: malaria vaccine candidate containing adjuvant Matrix-M™
Action mechanism:
Disease: malaria
Therapeutic area: Infectious diseases - Parasitic diseases
Country: UK
Trial
details: The phase I study will include approximately 25 volunteers and is planned to be completed by mid- 2013. The study aims to evaluate the safety and immunogenicity of the malaria vaccine candidate. The trial is sponsored by the University of Oxford and receives funding support from the National Institute for Health Research Oxford Biomedical Research Centre at The Oxford University Hospitals NHS Trust and the University of Oxford.
Latest
news: Isconova has announced that The Jenner Institute at Oxford University has received approval from Medicines and Healthcare products Regulatory Agency (MHRA) in the UK to initiate a phase I study with a malaria vaccine candidate, containing Isconova’s proprietary adjuvant Matrix-M™.The first volunteer has received the vaccine that is a combination of a viral vector encoding a malaria antigen developed by Oxford mixed with Matrix-M™.The study is the fourth phase I study to be initiated with Matrix-M™.
Provided that the development will be successful and lead to a partnership with a vaccine company for future commercialization, future revenues will be shared between the partners.
